Navigation Links
AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product in AM-Pharma's pipeline

BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis.

Plasma creatinine clearance, a marker for renal function, improved by 45% (median) in patients with Acute Renal Failure treated with Alkaline Phosphatase and deteriorated by 25% (median) in patients with Acute Renal Failure treated with placebo, with p values of < 0.05.


In addition, the level of glutathione-S-transferase-A1, a marker for kidney damage, decreased by 70% (median) in AP treated patients, compared to a 200% (median) increase in placebo treated patients, with p values again of < 0.05.


Fifteen patients (10 active, 5 placebo) with Acute Renal Failure were treated for 24 hours as part of a double-blind, randomized, placebo-controlled Phase IIa study in 36 Sepsis patients. The study took place in the Department of Intensive Care Medicine at the Radboud University Medical Centre, Nijmegen, The Netherlands.


Bart Wuurman, CEO of AM-Pharma commented on the positive results, saying: "We are very excited by the results in this Acute Renal Failure subgroup. It shows statistically significant and clinically relevant improvements in a condition that is very difficult to treat, has a high mortality rate and is associated with high costs through long term dialysis treatment. We now plan to explore the use of Alkaline Phosphatase in Acute Renal Failure in a separate study."


- ENDS -

Notes to editors:

About AM-Pharma www.am-pharma.com <




Page: 1 2 3

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/6/2009)...ov. 6 America,s Special... group of mid-market and smaller innovator pharmac...H.R. 3962, the "Affordable Health Care for America.... These smaller companies fear that the cumulativ... hinder their efforts to bring new medicines to ma...
(Date:11/6/2009)...ss., Nov. 6 Facet Solutions, Inc. ...sets of Archus Orthopedics. The acquisition create...erings, intellectual property and clinical experie...in for patients suffering from lumbar spinal steno... Geoff Pardo. "This consolidation further strengt...
(Date:11/6/2009)..., Nov. 6 Boston Scientif...it has reached an agreement in principle with the ...t advisories issued by its Guidant subsidiary in 2...ed prior to Boston Scientific,s 2006 acquisition o...disclosed an investigation by the U.S. Attorney,s ...
Breaking Medicine Technology:Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Facet Solutions Acquires Archus Orthopedics 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17IUPUI chemists develop Distributed Drug Discovery 3A Finding drugs for neglected diseases 48927 1IUPUI chemists develop Distributed Drug Discovery 3A Finding drugs for neglected diseases 48927 2IUPUI chemists develop Distributed Drug Discovery 3A Finding drugs for neglected diseases 48927 3Having a higher purpose in life reduces risk of death among older adults 48925 1Having a higher purpose in life reduces risk of death among older adults 48925 2Having a higher purpose in life reduces risk of death among older adults 48925 3They are young and need the job 3A A second chance for dangerous T cells 8838 1They are young and need the job 3A A second chance for dangerous T cells 8838 2They are young and need the job 3A A second chance for dangerous T cells 8838 3
...uticals, Inc. (Nasdaq: IDIX ), a biopharmaceutic...t of drugs for the treatment of human viral and ot...as initiated a proof-of-concept study of IDX184, a...he treatment of HCV under an Investigational New D...Administration (FDA). The study is evaluating IDX1...
...-B(R) for lupus and ABthrax(R) for inhalation anth...on - , , - GSK Phase 3 trial of darapladib underw...provides 2009 financial guidance; expects less tha... Jan. 12 Human Genome Sciences, Inc. (Nasdaq: H...d report on the Company,s progress toward commerci...
Other Medicine Technology:Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9
(Date:11/8/2009)...PRNewswire-USNewswire/ -- The American Public Heal...wellness provisions in the health reform bill pass... this bill, the House takes important steps toward...e reforms and moving our health system from one th...s on keeping people healthy," said Georges C. Benj...
(Date:11/8/2009)...W Academy of Health holds open house at Victoria c...us) November 8, 2009 -- UCW Academy of Health invi...lumbia’s health care industry to attend thei..., 2009. , ,UCW Academy of Health, which offers di...d social services, designs its programs to meet th...
(Date:11/8/2009)...Newswire-USNewswire/ -- Speaker Nancy Pelosi and D...g the House passage of H.R. 3962, the Affordable H...vote of 220 to 215. Below are the Speaker,s openi...st received a call from the President of the Unite...at victory for the American people. I thank the Pr...
(Date:11/8/2009)... Global Solutions is pleased to announce that it h...l effort for ReSound who recently received an awar...act. The award includes not only the Veterans Admi... other federal agencies. , ...al Solutions is pleased to announce that it has be...
(Date:11/8/2009)...jury of 8 people in the Western District of Pennsy...pain and suffering for a medical malpractice case....ia Nocera of Thomas E. Crenney and Associates, LLC... Monestersky and against the Uniontown Hospital. ... hysterectomy at age 18. , ...
Breaking Medicine News(10 mins):Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2
...ternational team of researchers were studying Bard... lacks proper functional cilia gets lodged in the...s which are in the brain which control appetite ar...kidney failure. Eight faulty genes are thought...
...vate hospital group in South Africa will be recrui...ff the country faces. // Estelle Jordaan, Directo...ily Beeld here that a team from the private hospit...stern Cape Province, where the shortage of staff i...
...tists have warned that the improper usage of MP3 a... can contribute towards affecting the hearing capa...n’s Director of Audiology Paul R. Kileny revealed ...use them for hours together, which will definitely...
...ren who suffer from limb disabilities are being pr... by India’s Paraplegia Hospital in the City of Ahe...nd it is providing the services without any public...the benefits of this program. The hospital'...
...ayne Katon, a professor of psychiatry at the Unive...patients who are treated for depression don’t show...ation in their habits. // But along with th...blished in the journal Annals of Family Medicine. ...
...tists belonging to the Brown University have revea...ted to the aging of the cells. // This conclusion ...tween 5 and 30 years, wherein it was found that as...f the body are linked may seem obvious, but the la...
Other Medicine News:Health News:Depression plays a vital role in Diabetes 2
Creatine Kinase Kinetic Reagent
Creatine Kinase-MB (CK-MB)
Magnesium
Glucose UV Liquidplus
Medicine Products: